All News

Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.

Online systems, including telehealth, are imperative to maintaining optimal care for patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic, said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers, in an interview with The American Journal of Managed Care® (AJMC®).

This week, the top managed care news included HHS' plans to allocate the remaining $70 billion in COVID-19 funding to providers; an analysis finding aggressive social distancing measures economically justified; highlights from this week's virtual Community Oncology Conference.

The FDA granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) as the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) that has spread to other parts of the body.

Visual impairment may be a risk factor for dementia, according to a study published in JAMA Ophthalmology in which researchers compared the likelihood of incident dementia or mild cognitive impairment among women with and without baseline visual impairment.

Nearly 5 in 10 individuals in the United States—150 million Americans—live where pollution levels are often too dangerous to breathe, according to the American Lung Association’s annual State of the Air Report, released today. Poor air quality has been linked to higher rates of chronic diseases, comorbidities, and poor health outcomes. Several studies suggest poor air quality is a contributing factor to the prevalence of coronavirus disease 2019 (COVID-10) in some communities.

CMS will allow clinicians who participate in the Quality Payment Program to earn credit in the Merit-based Incentive Payment System (MIPS) for participation in a coronavirus disease 2019 (COVID-19) clinical trial and reporting clinical information; President Trump announced via Twitter that he would sign an executive order to temporarily suspend immigration; findings from antibody testing in Los Angeles indicate that more people have been infected with COVID-19 than initially confirmed.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text